<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866955</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017788-40</org_study_id>
    <nct_id>NCT02866955</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.</brief_title>
  <acronym>EFESE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite advances in early detection and treatment strategy, about 25 to 40% of patients
      treated for breast cancer develop metastasis.

      Some patients are in a therapeutic impasse situation. It is therefore necessary to consider
      all possible options. The Estramustine showed encouraging results in the treatment of
      metastatic breast cancer.

      Given the clinical data, the answer rate of Estramustine and its impact on progression free
      survival deserve to be studied in earlier clinical situation.

      This Phase II study evaluated the efficacy of Estramustine in women with breast cancer and
      metastates, already treated with aromatase inhibitors and for whom this treatment has failed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival after a 6- month monotherapy with Estramustine in patients with HER2-/RH+ breast cancer progressing</measure>
    <time_frame>up to 6 months</time_frame>
    <description>proportion of patients in progression-free survival (PFS) after a 6-month treatment is defined as the duration of objective response or stabilisation of the disease according to the Recist criteria.
The following events shall be considered as progressive :
Relapse
Treatment intolerance leading to stop the treatment
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risks of thrombosis</measure>
    <time_frame>up to 6 months</time_frame>
    <description>risks of thrombosis assessed by the analysis of biomarkers (D-Dimer, prothrombin fragment 1+2, von Willebrand factor, fibrinogen, Chain Reaction Protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit of estramustine</measure>
    <time_frame>1 year</time_frame>
    <description>clinical benefit of estramustine assessed by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the answer rate and biomarkers</measure>
    <time_frame>1 year</time_frame>
    <description>answer rate (RECIST criteria) and level of biomarkers (Lactate déshydrogénase, Antigène carcino-embryonnaire and Cancer antigène 15-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of estramustine treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicity (Common Terminology Criteria for Adverse Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of tamoxifen treatments</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicity (Common Terminology Criteria for Adverse Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients developing thromboembolic events</measure>
    <time_frame>1 year</time_frame>
    <description>proportion of patients developing thromboembolic events assessed in the 2 groups every month during the one-year patient follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GROUP E (Estramustine)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP T (Tamoxifen)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estramustine</intervention_name>
    <description>140mg/4 caps/day</description>
    <arm_group_label>GROUP E (Estramustine)</arm_group_label>
    <other_name>estramustine phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20mg/day</description>
    <arm_group_label>GROUP T (Tamoxifen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women or women receiving Luteinizing hormone-releasing hormone (LHRH)
             analogs

          -  Histologically confirmed metastatic breast cancer RH+

          -  Measurable metastatic breast cancer (modified RECIST criteria) or not measurable but
             evaluable

          -  Recurrence:

               -  being treated with aromatase inhibitors (AIs)

               -  after adjuvant treatment by AIs

               -  after progression of the metastatic cancer in patients receiving AIs following
                  positive response during at least 6 months

          -  Performance status ≤ 2

          -  Haematological test: polynuclear neutrophiles ≥ 1.5 × 109 /L, haemoglobin ≥ 9 g/dL,
             blood platelet ≥ 100 × 109 /L

          -  Hepatic function: albumin ≥ 2.5 g/dL, serum bilirubin ≤ 1.5 × N (except if Gilbert's
             Syndrome) , aminotransferases ≤ 3 × N (≤ 5 × N if hepatic metastases)

          -  Renal function: serum creatinine ≤ 1.5 mg/dL or clearance of creatinine ≥ 40 ml/min

          -  Women without endometrial pathology

          -  Ability to provide written informed consent before the start of any study specific
             procedures

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Pre-menopausal, pregnant or pregnant or breast feeding females

          -  Patient who should exclusively be treated by chemotherapy

          -  Women previously treated with chemotherapy but not by AIs

          -  Women previously treated by tamoxifen for their metastatic breast cancer

          -  HER2+

          -  Concurrent anti-cancer treatment (chemotherapy, surgery, immunotherapy, biological
             therapy and tumour embolism)

          -  Concurrent treatment with protocol-defined prohibited medications

          -  Malabsorption syndrome , significant digestive dysfunction, gastrectomy, jejunectomy,
             hemorrhagic recto colon

          -  Concurrent disease or condition that may interfere with study participation, or any
             serious medical disorder that would interfere with the subject's safety (for example,
             active or uncontrolled infection or any psychiatric condition prohibiting
             understanding or rendering of informed consent)

          -  Any pathology, including severe psychiatric or psychologic disease that may harm
             patient's safety or participation in the study

          -  Serious or not cured or unstable toxicity due to the administration of another drug
             being involved in clinical trials

          -  Uncontrolled cardiovascular pathologies

          -  Previous history of thromboembolic event like deep vein thrombosis or pulmonary
             embolism recorded within one year before the inclusion date

          -  Active uncontrolled infection

          -  Existence of an increased risk of thromboembolic event, apart from the metastatic
             cancer condition, such as:

               -  known presence of antiphospholipid antibody

               -  family history of thrombophilia

               -  existence of any clinical, genetic, or biological abnormality which can increase
                  the risk of thromboembolic event according to the

          -  Participation to a clinical trial at least 4 weeks prior the start of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LUPORSI Elisabeth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GUASTALLA Jean Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CLCC Léon Bérard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GILLON Veronique</last_name>
    <phone>0033383598608</phone>
    <email>v.gillon@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES Laurinda</last_name>
    <phone>0033383598487</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serin Daniel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besançon-Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Villanueva Christian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laplaige Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zelek Laurent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dohollou Nadine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Hélène, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre O. Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonneterre Jacques, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guastalla Jean Paul, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Clairval</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hervé, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHBM Site du Mittan</name>
      <address>
        <city>Montbeliard</city>
        <zip>25200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Villanueva Christian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Val d'Aurel</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemanski Claire, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lortholary Alain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferrero Jean Marc, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gligorov Joseph, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Médioni Jacques, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eymard Jean-Christophe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Courlancy Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Facchini Thomas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique armoricaine</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Besson Dominique, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petit Thierry, md</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dourthe Louis-Marie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luporsi Elisabeth, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aromatase inhibitors</keyword>
  <keyword>Metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Estramustine</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

